
Repare Therapeutics | Synthetic Lethality Precision Oncology
Dec 24, 2025 · Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines.
Repare | Synthetic Lethality Precision Oncology | Pipeline
Check out the drug pipeline for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing synthetic lethal therapies.
Repare | Synthetic Lethality Precision Oncology | About
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We developed highly …
Repare Therapeutics | Precision Oncology | Investor Relations
Corporate Profile for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.
Repare | Synthetic Lethal Therapies | Discovery Platform
Learn about scientifc discovery platorm at Repare Therapeutics, a clinical-stage precision oncology company developing novel, synthetic lethal medicines.
Repare | Synthetic Lethality Precision Oncology | Leadership
Learn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.
Repare Therapeutics | Synthetic Lethality | Press Releases
4 days ago · Press releases for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.
Repare Therapeutics | Synthetic Lethality | Polϴ Inhibitor
Repare is developing a small molecule inhibitor of polymerase theta, or Polθ, a SL target associated with BRCA mutations and other genomic alterations.
Repare Therapeutics | Precision Oncology | Clinical Trials
Repare Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information for each study and site location.
Repare Therapeutics Announces a Worldwide License and …
Jun 1, 2022 · Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to …